VectivBio to be Acquired by Ironwood

Basel, Switzerland – May 23, 2023 – Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion. The deal was structured in a precedent-setting, all-cash tender offer for the Swiss Nasdaq-listed company. Partners Michal Berkner and Brandon Fenn led the Cooley team, along with associate Rita Sobral.

The acquisition of VectivBio and its lead investigational asset apraglutide provides a significant opportunity to accelerate the next growth horizon for Ironwood. The transaction has the potential to strengthen Ironwood’s innovative portfolio and pipeline to advance treatment for GI diseases and redefine the standard of care for GI patients.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.